Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


WHO pausing the hydroxycholoroquine arm of its global COVID-19 drug trials.

Written by | 27 May 2020 | COVID-19

The World Health Organization (WHO) is pausing the hydroxycholoroquine arm of its global COVID-19 drug trials after a review found the malaria therapy was associated with raised death rates and heart problems.The WHO’s decision follows a retrospective analysis of trials in 671 patients worldwide taking hydroxychloroquine or chloroquine, used alone or with a macrolide antibiotic (azithromycin, doxycycline) in hospital for COVID-19.

The observational research published in The Lancet concluded that the drug regimens were associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.